Liver carcinoma
|
0.700 |
Biomarker
|
disease |
MGD |
|
|
|
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Considering the strong association between the ratio of the methylated to unmethylated APC sequences in serum and the presence of portal vein thrombosis, methylation status of APC sequences could be a promising marker for improving HCC management.
|
23428864 |
2013 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas.
|
15067328 |
2004 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mutations of beta-catenin, APC, and axins are important but not frequent enough to be accountable for the accumulation of beta-catenin in human hepatocellular carcinoma (HCC).
|
17030191 |
2006 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, combined with an immunohistochemical analysis of the beta-catenin protein, this case provides the first evidence that genetic inactivation of the APC gene can play a significant role in the progression of sporadic HCC, probably by activating the Wnt/beta-catenin pathway.
|
16897741 |
2006 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In contrast to common HCC the APC and CDH1 (E-cadherin) genes were found devoid of any DNA methylation in FLC, whereas the GSTπ1 gene showed comparable DNA methylation in tumor and surrounding tissue at a moderate level.
|
21060828 |
2010 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The results suggested that the possibility of APC and MCC as the gene defect in the genesis of human hepatocellular carcinoma may be very rare.
|
10381126 |
1998 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The most frequently methylated TSGs in HCC were: SOCS-1 (65%), GSTP (54%), APC (53%), E-cadherin (49%), and p15 (49%).
|
12937151 |
2003 |
Liver carcinoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Promoter methylation of the APC gene seems to be of significance in hepatocarcinogenesis and results in reduced protein expression in HCC.
|
17973119 |
2008 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The genes frequently methylated in HCC were APC (81.7%), GSTP1 (76.7%), RASSF1A (66.7%), p16 (48.3%), COX-2 (35%), and E-cadherin (33.3%).
|
14507645 |
2003 |
Liver carcinoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
APC methylation was the highest in HCC group (70%).
|
29865038 |
2018 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
To the authors' knowledge, this study provides the first evidence that biallelic inactivation of the APC gene may contribute to the development of HCC in patients with FAP.
|
11466687 |
2001 |
Liver carcinoma
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this study, we examined beta-catenin and APC mutations in 22 HCCs associated with HCV infection, using single-strand conformation polymorphism (SSCP) followed by direct DNA sequencing. beta-Catenin mutations were found in nine (41%) cases, but no APC mutations were found. beta-Catenin immunohistochemistry revealed nuclear accumulation of beta-catenin protein in all nine tumors with a beta-catenin mutation and two additional tumors without a mutation.
|
10595907 |
1999 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The results confirm that the putative tumor suppressor gene for HCC without cirrhosis on chromosome 5q is distinct from the MCC and APC genes.
|
8402727 |
1993 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In our study, we screened HCCs resulting from HCV infection (51 cases), HBV infection (26 cases) or excess alcohol intake (23 cases) for alterations in genes involved in the RB1 pathway (p16(INK4a), p15(INK4b), RB1, CDK4 and cyclin D1), the p53 pathway (p53, p14(ARF) and MDM2) and the Wnt pathway (beta-catenin, APC).
|
12845670 |
2003 |
Liver carcinoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
The hypermethylation frequency of GSTP1 and RASSF1A showed significant difference between HCCs and liver cirrhosis with or without HBV infection (P<0.05), but differences of the hypermethylation status of APC, E-cadherin, and P16 were not statistically significant.
|
18691570 |
2008 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
DNA promoter methylation frequencies in HCC and matching non-malignant cirrhotic liver, respectively, were as follows: p16(INK4a) (76% vs. 24%), GSTP1 (53% vs. 32%), MGMT (6 vs. 12%), DAP-K (68 vs. 100%) and APC (100 vs. 100%).
|
18351580 |
2008 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Together, our findings unravel the LSD1/Prickle1/APC/β-catenin signaling axis as a novel molecular circuit regulating the stemness and chemoresistance of hepatic Lgr5(+) CICs and provide potential targets to improve chemotherapeutic efficacies against HCC.
|
25893304 |
2015 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
These results suggested that Emi1 participates in HCC cell proliferation and that progression is controlled by APC/C inhibition, which stabilized Skp2 and enabled p27(kip1) degradation.
|
22995332 |
2013 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The peptidyl-proplyl-isomerase, PIN1, upregulates beta-catenin by inhibiting its interaction with APC. beta-catenin accumulation occurs in about 70% of hepatocellular carcinoma (HCC), of which only 20% are due to beta-catenin mutations.
|
15064734 |
2004 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Epigenetic inactivation of tumor suppressor genes like RASSF1A or APC by overexpression of DNA methyltransferases (DNMTs) has been shown to be common in HCC and to be linked to the overall prognosis of patients.
|
22943463 |
2012 |